{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-016210","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.269553+00:00","generated_at":"2026-05-17T05:15:32.462443+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lipocine LPCN 1154 Phase 3 PPD trial: 1/3 randomized; topline 2Q26; DSMB review 4Q25","bullets":["One-third of planned patients randomized in LPCN 1154 Phase 3 trial for postpartum depression.","Topline results expected in second quarter 2026.","Independent DSMB safety review planned for fourth quarter 2025; update post-DSMB.","Trial conducted entirely outpatient; no medical monitoring by HCP required per FDA feedback.","CEO Mahesh Patel states LPCN 1154 can become standard of care; 505(b)(2) NDA submission targeted in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-016210","json":"https://secwatch.observer/filing/0001493152-25-016210.json","markdown":"https://secwatch.observer/filing/0001493152-25-016210.md","text":"https://secwatch.observer/filing/0001493152-25-016210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225016210/0001493152-25-016210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225016210/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:15:32.462443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}